← Back to Analyst Consensus 
ROIV Buy
Roivant Sciences Ltd.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 1 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | Wolfe Research | downgrade | Outperform → Peer Perform | — | 53% |
| Sep 17, 2026 | Stifel | initiate | — → Buy | — | 53% |
| Sep 9, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Sep 9, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Sep 8, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 8, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Aug 28, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 10, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 7, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 7, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 26, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 21, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| May 21, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| May 21, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 16, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Mar 4, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Feb 10, 2026 | Citigroup | maintain | Buy → Buy | $35 | 54% |
| Feb 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $33 | 44% |
| Feb 9, 2026 | Guggenheim | maintain | Buy → Buy | $30 | 52% |
| Dec 15, 2025 | Leerink Partners | maintain | Outperform → Outperform | $32 | 51% |
| Dec 15, 2025 | Goldman Sachs | maintain | Buy → Buy | $33 | 54% |
| Dec 12, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $26 | 44% |
| Nov 11, 2025 | Citigroup | maintain | Buy → Buy | $26 | 54% |
| Oct 29, 2025 | Citigroup | maintain | Buy → Buy | $25 | 54% |
| Sep 18, 2025 | Goldman Sachs | maintain | Buy → Buy | $24 | 54% |
| Sep 18, 2025 | Jefferies | maintain | Buy → Buy | $20 | 52% |
| Sep 18, 2025 | JP Morgan | maintain | Overweight → Overweight | $20 | 54% |
| Sep 18, 2025 | Guggenheim | maintain | Buy → Buy | $21 | 52% |
| Sep 18, 2025 | Leerink Partners | maintain | Outperform → Outperform | $22 | 51% |
| Sep 18, 2025 | B of A Securities | maintain | Neutral → Neutral | $16.5 | 53% |
| Sep 18, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Sep 2, 2025 | Citigroup | initiate | — → Buy | $16 | 54% |
| Jun 18, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| May 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Apr 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Feb 11, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Nov 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Sep 19, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Sep 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Sep 11, 2024 | B of A Securities | maintain | Neutral → Neutral | $12.5 | 53% |
| Sep 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Sep 9, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Aug 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Jul 10, 2024 | Piper Sandler | maintain | Overweight → Overweight | $22 | 54% |
| Jun 18, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| May 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Apr 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Apr 3, 2024 | Goldman Sachs | maintain | Buy → Buy | $18 | 54% |
| Apr 3, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $18 | 44% |
| Apr 3, 2024 | Deutsche Bank | maintain | Buy → Buy | $15 | 57% |
Price Target Trend
Jun 14, 2026 Latest: $48.91 Oct 25, 2026
EPS Estimates
0y $-1.58
Lo: $-1.96 Hi: $-1.23
3 analysts +1q $-0.41
Lo: $-0.53 Hi: $-0.35
3 analysts 0q $-0.45
Lo: $-0.59 Hi: $-0.35
3 analysts +1y $-1.72
Lo: $-2.10 Hi: $-1.27
3 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days